Prescriber, operator, purchaser, payer and patient — separate incentives — internal hemorrhoids office based treatment

1. Summary

The domain dossier flagged this section as entirely unsearched and sketched five parties — prescriber, operator, purchaser, payer, patient — without evidence for any of them. This pass finds that for office-based grade I-III hemorrhoid treatment, the prescriber and operator are usually the same clinician, and two independent professional-society guideline documents each name their own specialty as an appropriate performer of the office procedure without either document claiming exclusive ownership [1][2]. The purchaser and payer incentives are structurally linked: a specific federal regulation lets the same physician group both refer and personally furnish the procedure without triggering the self-referral prohibition [7], and CMS's own CY2026 payment file shows that performing the same procedure in the office rather than a facility pays the practice a materially higher amount [8]. The regional Medicare coverage policy gates that payment on documented conservative-therapy failure and grade-specific findings [6]. The only patient-side evidence located this pass is a single non-US randomized trial reporting that patients experienced markedly different trade-offs — pain, recovery time, recurrence — between office banding and surgery, and that the trial's own recruitment was complicated by how strongly patients already held treatment preferences [5].

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Prescriber / decider — two guideline bodies, neither claiming exclusivity

Two independent, non-affiliated professional-society sources each name a role for their own specialty in deciding and delivering office hemorrhoid treatment, and neither source denies the other's specialty a role — read together, they establish that office hemorrhoid care is not a single-specialty prescriber domain. The AGA's 2026 Clinical Practice Update states plainly: "The diagnosis and treatment of hemorrhoids is within the purview of the gastroenterologist" [1]. Separately, a peer-reviewed AAFP summary of the 2024 ASCRS clinical practice guideline states that rubber band ligation "is performed by surgeons or primary care physicians in-office" [2] [single-source]. The ASCRS guideline itself (PMID 38294832) carries no abstract in PubMed and its full text was not retrieved this pass — its content beyond what the AAFP summary reports is unread [3] [paywalled]. No source located this pass names nurse practitioners or physician assistants as independent deciders of which procedure to perform, as distinct from the licensure role described below.

Operator — usually the same clinician who decides, with a distinct licensure allowance underneath

Everything found this pass is consistent with the office procedure being performed at the same visit by the same clinician who made the treatment decision, rather than handed to separate ancillary staff — no source contradicts this, but no source states it as its own finding either. One licensure-specific fact does bear on who may act short of the physician: the Medicare local coverage determination for infrared coagulation states that "for outpatient settings other than a Comprehensive Outpatient Rehabilitation Facility (CORF), references to 'physicians' throughout this policy include nonphysicians, such as nurse practitioners, clinical nurse specialists and physician assistants. Such nonphysician practitioners, with certain exceptions, may certify, order and establish the plan of care as authorized by state law" [6] [single-source]. This authorizes ordering and plan-of-care responsibility, not necessarily hands-on delivery of the destruction procedure itself, and the LCD does not separately address who may perform the physical banding or coagulation. A non-US data point, included for shape rather than as a US finding: an 18-surgeon Italian registry of 32,458 patients treated over 17 years found that "Grade II haemorrhoids were treated with rubber band ligation in over 90% of the cases" [4] [single-source], but every treating clinician in that series was a colorectal surgeon by design of the survey, so it cannot speak to the US multi-specialty picture described above.

Purchaser — the same practice that decides and performs also captures the site-of-service premium

Two registry facts, read together, describe a structural purchaser incentive rather than establishing what any purchaser has actually chosen to do. First, the physician self-referral exception at 42 CFR 411.355(b) permits in-office ancillary services — including services "furnished personally by ... the referring physician or a physician who is a member of the same group practice" — without triggering the Stark Law referral prohibition, provided the location and supervision conditions in the same section are met [7] [single-source]. Second, CMS's own CY2026 Physician Fee Schedule payment file, fetched directly this pass, shows HCPCS 46930 (destruction of internal hemorrhoids) carries a total RVU of 7.42 in the non-facility (office) setting versus 4.72 in the facility setting [8] [single-source]. Applying the two CY2026 conversion factors present in the same file (33.4009 and 33.5675, with no column in the file distinguishing which billing scenario each applies to) yields a computed national, unadjusted payment of roughly $247.83–$249.07 in the office setting against roughly $157.65–$158.44 in a facility — a difference of about $90 per case that accrues to whichever entity bills the non-facility rate [8] [single-source]. Neither source states that this differential drives any actual purchasing or site-of-service decision; that would be a class-3 question about intent (see §5).

Payer — documentation-gated coverage, regionally scoped

The one payer-policy document read this pass ties coverage to specific, checkable documentation rather than to clinician judgment alone: medical necessity requires "history and physical findings supporting a diagnosis of symptomatic Grade I, Grade II or Grade III hemorrhoids," a record of conservative treatment tried and its response, and for a repeat procedure, that "a reasonable amount of time has elapsed to prove failure from the first treatment" [6] [single-source]. This is a regional Medicare contractor policy (Palmetto GBA, DME MAC Jurisdiction J), not a national coverage determination, and no equivalent policy from another Medicare Administrative Contractor or from a commercial payer was located this pass.

Patient — the one located data point is a trade-off, not a preference survey

No US patient-preference, satisfaction, or discontinuation-reason study for office hemorrhoid treatment was located this pass. The single located data point is a 10-Dutch-hospital randomized noninferiority trial (n=87: 47 rubber band ligation, 40 hemorrhoidectomy, grade III disease, 2019–2022) that measured — rather than asked about — the trade-off patients actually experienced: rubber band ligation patients returned to work sooner (1 vs 9 days, p=0.021) and reported lower first-week pain (VAS 1 vs 4, p=0.002), but the ligation group had worse 12-month recurrence (47.5% vs 6.1%) and "patient-reported hemorrhoidal symptom scores favored hemorrhoidectomy" [5] [single-source]. The same trial report states its own recruitment "was hindered by significant treatment preferences and the COVID-19 pandemic" [5] [single-source] — a reported fact about what happened during enrollment, not a synthesized opinion about what patients would choose. Separately, the AGA update states that "as part of informed consent for hemorrhoid therapies, the patient must be made aware of the small possibility of pelvic sepsis as a complication" [1] [single-source], naming one specific risk-disclosure burden placed on the patient regardless of which office modality is chosen.

4. Sources

[1] AGA Clinical Practice Update on Diagnosis and Treatment of Hemorrhoids: Expert Review — Clinical Gastroenterology and Hepatology (published 2026, month not given in the PubMed record; accessed 2026-09-01). PMID 42067175 — https://pubmed.ncbi.nlm.nih.gov/42067175/ [peer-reviewed] [2] Management of Hemorrhoids: Guidelines From the ASCRS — American Family Physician / AAFP (published 2025-12, day not given in the journal record; accessed 2026-09-01). PMID 41533423 — https://www.aafp.org/pubs/afp/issues/2025/1200/practice-guidelines-hemorrhoids.html [guideline] [3] The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Hemorrhoids — Diseases of the Colon & Rectum (published 2024, month not given in the PubMed record; accessed 2026-09-01). PMID 38294832 — https://pubmed.ncbi.nlm.nih.gov/38294832/ [guideline] [4] Surgical management of haemorrhoids: an Italian survey of over 32,000 patients over 17 years — Colorectal Disease (published 2018-12, day not given in the PubMed record; accessed 2026-09-01). PMID 30004171 — https://pubmed.ncbi.nlm.nih.gov/30004171/ [peer-reviewed] [5] Comparison of Rubber Band Ligation and Hemorrhoidectomy in Patients With Symptomatic Hemorrhoids Grade III: A Multicenter, Open-Label, Randomized Controlled Noninferiority Trial — Diseases of the Colon & Rectum (published 2025, month not given in the PubMed record; accessed 2026-09-01). PMID 39952268, trial registration NCT04621695 — https://pubmed.ncbi.nlm.nih.gov/39952268/ [peer-reviewed] [6] Infrared Coagulation (IRC) of Hemorrhoids, Local Coverage Determination — Centers for Medicare & Medicaid Services, contractor Palmetto GBA, DME MAC Jurisdiction J (revision effective 2023-07-06; accessed 2026-09-01 via the MCD Archive, document version 36). LCD 34422 (L34422) — https://localcoverage.cms.gov/mcd_archive/view/lcd.aspx?lcdInfo=34422:36 [payer-policy] [7] Electronic Code of Federal Regulations, Title 42, Part 411, Subpart J — General exceptions to the referral prohibition related to both ownership/investment and compensation — eCFR, National Archives and Records Administration / GPO (issue date 2026-08-13; accessed 2026-09-01). 42 CFR 411.355(b) — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-411/subpart-J/section-411.355 [federal-registry] [8] CY2026 Medicare Physician Fee Schedule national payment amount indicator file ("Indicators for 2026"), implementing the CY 2026 PFS final rule — Centers for Medicare & Medicaid Services, pfs.data.cms.gov (rule published 2025-11-05; file accessed 2026-09-01). FR Doc. 2025-19787 (90 FR 49266) — https://pfs.data.cms.gov/sites/default/files/data/indicators2026-07-01-2026.csv [federal-registry]

5. Sourcing & Gaps

Well established: that office hemorrhoid care is not owned exclusively by one physician specialty rests on two independent, non-affiliated professional-society sources that each name a role for their own specialty without denying the other's [1][2], stated plainly in §3. Everything else in this report is a single finding resting on one document.

Thin: the operator identity (§3), the purchaser incentive structure (§3), the payer documentation requirements (§3), and the patient trade-off data (§3) each rest on exactly one source, individually marked [single-source]. The ASCRS 2024 guideline itself was not read beyond its AAFP summary and is marked [paywalled].

Rescoped from class 3: "Would primary care physicians rather perform hemorrhoid banding themselves than refer to a specialist?" has no answerable form; its twin — which specialties current guideline documents name as legitimate performers, and what each says about referral — is answered in §3 from [1] and [2]. "Would a practice choose to keep this procedure in-office for the money?" is unanswerable directly; its twin — what CMS's own non-facility-versus-facility RVU figures actually pay, and what federal self-referral regulation permits for in-office ancillary services — is answered from [7] and [8]. "Would patients prefer banding over hemorrhoidectomy at grade III?" is unanswerable directly; its twin — what patients in the one RCT that randomized this choice actually experienced on pain, recovery time, symptom scores and recurrence, and what the trial's own recruitment record says about how strongly they already held preferences — is answered from [5].

Out of scope: CPT descriptor text (AMA-licensed, never reproduced — only code numbers are used here); MAUDE device-complaint narratives (no connector in this repo); the Italian [4] and Dutch [5] data are non-US and are used only as directional context, never as evidence of a US practice pattern or a US patient population.

Not searched vs. not found: Not searched this pass — a CMS Part B utilization file breaking down which specialty bills 46930/46945/46946 most often; any commercial (non-Medicare) payer's coverage policy for hemorrhoid destruction; any other Medicare Administrative Contractor's LCD, to test whether [6]'s documentation requirements are contractor-specific or effectively national; the practice's capital-cost side of the purchaser incentive (device and consumable acquisition cost), as distinct from the payment-rate side covered here; any survey instrument or shared-decision-making tool specific to hemorrhoid treatment choice. Not found — a US-population patient-preference, satisfaction, or discontinuation-reason study for office rubber band ligation, infrared coagulation, or sclerotherapy; any primary document recording a direct scope-of-practice dispute between AGA and ASCRS (a WebSearch surfaced only third-party guideline-comparison pages, none of which were used as a source of record here).

[inference] That the same clinician can occupy the prescriber, operator and purchaser roles for this procedure — and is shielded from Stark Law liability for doing so by the in-office ancillary services exception, while also collecting a higher CMS payment for keeping the procedure in that setting — is this report's own synthesis across [1], [2], [7] and [8]. No single source states this combination; each source states only its own piece.

6. Claim Candidates